Medical network - March 24 in fujian ten marked "paid", the Beijing government has to separate "medicine". Fujian solution is to change medicine, Beijing solution to the medical, one to the left, one to the right, or Beijing, fujian province, which is policy vane?
Policy design point of view, fujian and Beijing obvious distinction:
Fujian, fully give play to the role of market mechanism, squeeze the drug prices artificially high space
Beijing: gradually break with medicine medicine, establish a scientific and reasonable compensation mechanism
▍ see directory
1, procurement directory
The catalog of fujian joint limit sunlight procurement, 1697 western medicine, Chinese medicine, 556.
Beijing directory: all varieties hang net price
List 2,
Fujian: joint purchasing price bidding hang web directory (a few enterprises)
Beijing: all hang web directory, unified big hospitals and grassroots health institutions purchasing and reimbursement directory (most)
▍ see prices
1, the retail price
Fujian: "health care the highest selling price" as the medical institutions and retail price ceiling
Beijing: all drugs zero rate of sales
2, the reimbursement price
Fujian: according to the drug properties (treatment), auxiliary, nourishment, respectively formulate medical insurance payment settlement price (and ginseng protect personal reimbursement ratio according to the medical insurance fund share, higher than health care the highest selling price part shall be borne by the medical establishment, higher than the medical insurance payment settlement price, lower than health care the difference between the highest selling price shall be borne by the individual.
Beijing: the actual retail prices of medical institutions (and ginseng protect personal reimbursement ratio according to the medical insurance fund share)
▍ hospital income
Fujian: drug purchase price, the medical institutions shall be in accordance with the highest selling price is not higher than health. The difference between the drug purchase price and sale price, medical institutions.
Beijing: cancel the drug addition, set up the medical service charge. Hospital income is mainly made up of medical services and classification of financial compensation.
▍ see patients
Fujian: drugs than medicare payment settlement price, lower than health care the difference between the highest selling price + medicine health care payment settlement price individual share part + other costs associated with the treatment.
Beijing: drug personal reimbursement ratio according to the actual retail price of medical institutions to share part + medical service charge pays amount + other costs associated with the treatment
▍ two votes and drug prices
Fujian: the drug distribution "of two votes. Encourage each district medical institutions on the platform, on the basis of the net price further negotiate with the enterprise to bring the bargaining. Hang net price for the country, such as net price above the provincial level of the minimum purchase price, enterprises should take the initiative to report to the provincial platform and make the price adjustment, if not timely report, once found to verify, will be suspended on the net pricing, forced to cancel the net on good faith enterprise" blacklist ".
Two votes. Beijing: the implementation of the drug distribution "encourage and regulate group purchasing, medical consortium purchasing and regional joint procurement, further improve the participation in the drug centralized purchasing of medical institutions, to lower the price of medicines and chemical reagents, consumables. Drug purchase in the government of all drug centralized purchasing platform, online drug purchase price with the provincial drug centralized purchasing the minimum price dynamic linkage.
Total knot
Two seemingly opposite policy design, in the admittance catalogue price, sales expenses and medical payments have very big difference, but in terms of lower prices is "the same formula, the same taste. No matter to the left or right, drug companies are ready to channel reconstruction and the price of products. For drug companies, the future I want to only "adaptation is king, research and development is the future".
Remember after
Health reform should not only satisfy medical institutions and relevant departments of health, and should be national and public satisfaction, rest assured, let pharmaceutical enterprises to participate in health care; Should not only health care experts took the heaven and earth, should listen to more common voice of the related industries, enterprises and the general public, difficulty and high cost of real understanding of the present stage people see a doctor is really solved. Let reform bring people health fresh air, more bring the progress of science and technology development, with more professional spirit to promote health, to benefit the people. |
